
Takumu Hasebe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4470545/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Daikenchuto (TUâ€100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K. Pharmacology Research and Perspectives, 2016, 4, e00215.	1.1	34
2	Augmented hepatic <scp>T</scp> ollâ€like receptors by fatty acids trigger the proâ€inflammatory state of nonâ€alcoholic fatty liver disease in mice. Hepatology Research, 2014, 44, 920-934.	1.8	30
3	Nonâ€alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1042-1048.	1.4	29
4	Butyrate and bioactive proteolytic form of Wnt-5a regulate colonic epithelial proliferation and spatial development. Scientific Reports, 2016, 6, 32094.	1.6	28
5	Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature. Internal Medicine, 2019, 58, 1747-1752.	0.3	23
6	TU-100 (Daikenchuto) and Ginger Ameliorate Anti-CD3 Antibody Induced T Cell-Mediated Murine Enteritis: Microbe-Independent Effects Involving Akt and NF-ήB Suppression. PLoS ONE, 2014, 9, e97456.	1.1	19
7	Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model. Journal of Gastroenterology, 2017, 52, 341-351.	2.3	17
8	Polymorphism of receptorâ€ŧype tyrosineâ€protein phosphatase delta gene in the development of nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 283-290.	1.4	15
9	Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment. JGH Open, 2019, 3, 329-337.	0.7	11
10	Daikenchuto (TUâ€100) Suppresses Tumor Development in the Azoxymethane and APC ^{min/+} Mouse Models of Experimental Colon Cancer. Phytotherapy Research, 2017, 31, 90-99.	2.8	10
11	Long-term growth of intrahepatic papillary neoplasms: A case report. World Journal of Gastroenterology, 2019, 25, 5569-5577.	1.4	7
12	Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib. Internal Medicine, 2020, 59, 657-662.	0.3	5
13	Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. World Journal of Gastroenterology, 2017, 23, 5823.	1.4	5
14	Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumorâ€platelet interactions. International Journal of Cancer, 2022, 150, 1640-1653.	2.3	4
15	A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events. Internal Medicine, 2022, , .	0.3	4
16	A selective splicing variant of hepcidin mRNA in hepatocellular carcinoma cell lines. Biochemical and Biophysical Research Communications, 2016, 476, 501-507.	1.0	2
17	Effective Control of Relapsing Disseminated Intravascular Coagulation in a Patient with Decompensated Liver Cirrhosis by Recombinant Soluble Thrombomodulin. Internal Medicine, 2014, 53, 29-33.	0.3	1
18	Effectiveness of pazopanib for postoperative recurrence of granulocyte colony-stimulating factor-producing primary hepatic angiosarcoma. International Cancer Conference Journal, 2015, 4, 41-47.	0.2	1

Такими Наѕеве

#	Article	IF	CITATIONS
19	Conservative treatment of lamivudine-induced rhabdomyolysis in a patient with acute exacerbation of chronic hepatitis B. Acta Hepatologica Japonica, 2015, 56, 341-347.	0.0	1
20	Brain metastasis from hepatic cholangiolocellular carcinoma in a young female without chronic liver disease. Digestive and Liver Disease, 2020, 53, 1206-1207.	0.4	0
21	Submarine volcanic eruption of esophageal varices induced by failed variceal ligation and identified by the gel immersion method. Digestive Endoscopy, 2022, 34, .	1.3	Ο